Anthony Shock PhD

Anthony Shock, Ph.D. is a Director at the UCB Pharma, United Kingdom. Anthony Shock received his Ph.D. in Biochemistry from the University of London in 1987 followed by post-doctoral work at the National Heart and Lung Institute in London. He was then employed by a Biotech company called Celltech which eventually transformed into the global biopharmaceutical company, UCB. He has researched a wide range of drug targets, both small molecule- and antibody-based therapies, including two antibody targets that have been evaluated in patients with systemic lupus erythematosus, namely epratuzumab and dapirolizumab pegol.